This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cencora Q4 Earnings & Revenues Beat Estimates, Margins Decline Y/Y
by Zacks Equity Research
COR's fourth-quarter fiscal 2024 results showcase a strong segmental performance.
Fresenius Medical Q3 Earnings Beat Estimates, Operating Margin Rises
by Zacks Equity Research
FMS' third-quarter results showcase a strong segmental performance. The company raises its full-year 2024 outlook for operating income.
Ontrak, Inc. (OTRK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Ontrak (OTRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
TEM's third-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.
GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Glaukos' third-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.
Addus HomeCare (ADUS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 0.78% and 0.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
RVTY Q3 Earnings & Revenues Beat Estimates, Guidance Revised
by Zacks Equity Research
Revvity's third-quarter results showcase strong growth in Diagnostics business, along with a decline in Life Sciences segmental sales.
RadNet (RDNT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
RadNet (RDNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BDX Stock Declines Despite Launching BD IO Vascular Access System
by Zacks Equity Research
BD announces the BD Intraosseous Vascular Access System to enable quick vascular access for critical care situations.
Stryker Stock Gains on Q3 Earnings Beat & Raised Guidance
by Zacks Equity Research
SYK's third-quarter results reflect strong segmental performance, along with a rise in operating margin.
Option Care (OPCH) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 32.26% and 4.69%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
DaVita HealthCare (DVA) Q3 Earnings Miss Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of -6.16% and 1.29%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
ECL Q3 Earnings Surpass Estimates, Revenues Miss, Margins Rise
by Zacks Equity Research
Ecolab's robust performance across the majority of its segments drives its third-quarter sales.
AMIS Stock Surges After RF Ablation Trial Unveils Positive Results
by Zacks Equity Research
Autonomix's RF ablation trial for pancreatic cancer pain shows early success, enabling significant pain relief and opioid elimination in responding patients.
Here's Why You Should Add Veeva Stock in Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio raises optimism about the stock. However, escalating costs are concerning.
ALGN Stock Rise on the Release of Invisalign Smile Architect Software
by Zacks Equity Research
Align Technology unveils Invisalign Smile Architect software with Multiple Treatment Plans for providing customised treatment.
Dentsply Sirona Shares Fall After Suspension of Byte Aligner Products
by Zacks Equity Research
XRAY suspends Byte Aligner sales, citing regulatory review with the FDA, shifting resources to bolster other business areas amid compliance efforts.
Integer Holdings Q3 Earnings Surpass Estimates, Revenues Up Y/Y
by Zacks Equity Research
ITGR's third-quarter results reflect solid Medical sales and margin expansion amid the divestiture of its Electrochem business.
DexCom Q3 Earnings Beat Estimates on Sensor Growth, Stock Rises
by Zacks Equity Research
DXCM's third-quarter 2024 earnings and revenues surpass expectations, fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
ALUR Stock Declines Despite Submitting PMA for Allurion Balloon
by Zacks Equity Research
Allurion submits the first three modules of PMA application to the FDA for the Allurion Balloon.
Talkspace Shares Decline Despite Partnership With Wisdo Health
by Zacks Equity Research
TALK collaborates with Wisdo Health to enhance mental health support for seniors, addressing loneliness and improving access to care for the 65+ community.
LifeMD Shares Decline Even After the Launch of Testosterone Therapy
by Zacks Equity Research
LFMD expands its men's health services with TestoRx, offering convenient testosterone therapy and alternative treatments for low testosterone via telehealth.
ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE
by Zacks Equity Research
AngioDynamics announces the receipt of CPT Category I code for IRE technology.
Reasons to Retain Ecolab Stock in Your Portfolio for Now
by Zacks Equity Research
ECL's focus on cost-efficiency programs raises optimism about the stock.
Revvity Shares Decline Despite Launch of Transcribe AI Solution
by Zacks Equity Research
RVTY introduces Transcribe AI that digitizes handwritten test request forms, improving workflow speed and reducing manual data entry errors.